Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer

niversity of Oxford0 个研究点目标入组 25 人开始时间: 2022年8月16日最近更新: 2023年12月19日

适应症

试验速览

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37709321/ (added 15/09/2023)

•1. Participants must be fit and scheduled to receive MRgRT for pancreatic cancer. There are no specific restrictions on tumour size, number or interval from diagnosis
•2. Localised pancreatic cancer, which may be
•2.1. Locally advanced and inoperable pancreatic cancer
•2.2. Inoperable on medical grounds
•2.3. Operable, but patient declines surgery
•2.4. Locally recurrent pancreatic cancer
•3. Histologically proven pancreatic ductal adenocarcinoma or cytological proven pancreatic malignancy. Where histology/cytology is ‘suspicious’ MDT should confirm that it is appropriate to treat as malignancy
•4. Male or Female, aged 16 years or above
•5. Life expectancy of at least 6 months
•6. ECOG performance status 0-1
•7. Haematological and biochemical indices within defined ranges:
•7.1. Haemoglobin (Hb)=8.0 g/dL
•7.2. Platelet count =50 x 10e9/l
•7.3. Neutrophils =1.0 x 10e9/l
•7.4. Total bilirubin =1.5 x IULN
•7.5. AST(SGOT) or ALT(SGPT) = 3.0 x IULN
•8. Able (in the investigators’ opinion) and willing to comply with all study requirements for the duration of the study
•9. Willing and able to give informed consent

•1. Patients with specific MRI exclusion criteria – metallic implants, shrapnel, claustrophobia or other expected intolerance of prolonged (up to 90 minutes) stay in an MRI scanner
•2. Prior radiotherapy to the upper abdomen
•3. Pregnant or breastfeeding women, or women of childbearing potential unless effective methods of contraception are used. Male patients who do not agree to use a condom during RT treatment and for 3 months after or who are not surgically sterile.
•4. Distant metastatic disease or local disease that cannot be encompassed in the SBRT field

发起方